FBXW7/hCDC4 is a general tumor suppressor in human cancer

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9006-9012

  Akhoondi, Shahab ^a   Sun, Dahui ^b   Von Der Lehr, Natalie ^a   Apostolidou, Sophia ^c   Klotz, Kathleen ^b   Maljukova, Alena ^a   Cepeda, Diana ^a   Fiegl, Heidi ^c   Dofou, Dimitra ^c   Marth, Christian ^d   Mueller Holzner, Elisabeth ^d   Corcoran, Martin ^a   Dagnell, Markus ^a   Nejad, Sepideh Zabihi ^e   Nayer, Babak Noori ^e   Zali, Mohammad Reza ^e   Hansson, Johan ^a   Egyhazi, Susanne ^a   Petersson, Fredrik ^a   Sangfelt, Per ^f   Nordgren, Hans ^f   Grander, Dan ^a   Reed, Steven I ^g   Widschwendter, Martin ^c   Sangfelt, Olle ^a   Spruck, Charles ^b   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIN E1; F BOX PROTEIN; GENE PRODUCT; MUTANT PROTEIN; MYC PROTEIN; NOTCH RECEPTOR; ONCOPROTEIN; PROTEASOME; PROTEIN C JUN; PROTEIN FBXW7; PROTEIN HCDC4; PROTEIN P53; UBIQUITIN; UBIQUITIN LIGASE SCF; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CELL DIVISION; COLON CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; FBXW7 GENE; GENE FREQUENCY; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC SCREENING; HCDC4 GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; STOMACH CANCER; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE; WILD TYPE;

5-METHYLCYTOSINE; AMINATION; CELL CYCLE PROTEINS; DINUCLEOTIDE REPEATS; DNA METHYLATION; F-BOX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PROTEIN ISOFORMS; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASES;

EID: 35148842479     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1320     Document Type: Article

References (20)

1. Reed SI. The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ 2006;42:147-81.
2. Minella AC, Clurman BE. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 2005;4:1356-9.
3. Nash P, Tang X, Orlicky S, et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 2001;414:514-21.
4. Mao JH, Perez-Losada J, Wu D, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004;432:775-9.
5. Rajagopalan H, Jallepalli PV, Rago C, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004;428:77-81.
6. Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res 2002;62:4535-9.
7. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J Natl Cancer Inst 2000;92:826-32.
8. Lundgren C, Auer G, Frankendal B, et al. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002;12:110-8.
9. Kemp Z, Rowan A, Chambers W, et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res 2005;65:11361-6.
10. Cassia R, Moreno-Bueno G, Rodriguez-Perales S, et al. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003;201:589-95.
11. Sterian A, Kan T, Berki AT, et al. Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma. Oncology 2006;70:168-72.
12. Nowak D, Mossner M, Baldus CD, et al. Mutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism. Int J Med Sci 2006;3:148-51.
13. Woo LJ, Hwa SY, Young KS, et al. Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas. Acta Oncol 2006;45:487-8.
14. Yan T, Wunder JS, Gokgoz N, et al. hCDC4 variation in osteosarcoma. Cancer Genet Cytogenet 2006;169:138-42.
15. Kwak EL, Moberg KH, Wahrer DC, et al. Infrequent mutations of archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol 2005;98:124-8.
16. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003;163:1255-60.
17. Lee JW, Soung HY, Kim HJ, et al. Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer 2006;42:2369-73.
18. Jones PA. DNA methylation and cancer. Oncogene 2002;21:5358-60.
19. Zhang W, Koepp DM. Fbw7 isoform interaction contributes to cyclin E proteolysis. Mol Cancer Res 2006;4:935-43.
20. Van Drogen F, Sangfelt O, Malyukova A, et al. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell 2006;23:37-48.